TNFα AND ITS RECEPTORS IN PSORIATIC SKIN, BEFORE AND AFTER TREATMENT WITH ETANERCEPT
TNFα AND ITS RECEPTORS IN PSORIATIC SKIN, BEFORE AND AFTER TREATMENT WITH ETANERCEPT
复制标题
DOI：
10.1177/039463200902200411
复制
发表时间：
2009-10-01
影响因子：
3.5
通讯作者：
Feliciani, C.
中科院分区：
文献类型：
--
作者：
Caldarola, G.;De Simone, C.;Feliciani, C.
银屑病是一种慢性炎症性皮肤病，其特征在于炎症性真皮浸润和过度增殖的角质形成细胞。这种疾病的发病机制是由先天免疫和细胞因子产生的失调介导的。肿瘤坏死因子α（TNF α）被认为是参与银屑病病理机制的最重要的细胞因子。最近，已经引入了几种治疗银屑病的疗法，试图阻断TNF α活性。在这些治疗中，依那西普是一种特异性靶向TNF α的融合蛋白。我们对12名银屑病患者进行了一项研究，旨在评估依那西普治疗对病变和未受累银屑病皮肤中TNF α及其受体产生和表达的影响。我们证实，依那西普50 mg/周治疗3个月后，患者皮损和非皮损皮肤样本中的TNF、TNF-RI和TNF-RII免疫染色大大降低，表明这种治疗不仅作用于稳定的皮损斑块，而且作用于疾病的非常早期阶段。
Psoriasis is a chronic inflammatory skin condition characterized by inflammatory dermal infiltrate and hyperproliferative keratinocytes. The pathogenesis of this disease is mediated by a dysregulation of the innate immunity and cytokine production. Tumor Necrosis Factor alpha (TNF alpha) is considered the most important cytokine involved in the pathological mechanism of psoriasis. Recently, several therapies have been introduced for the treatment of psoriasis that try to block TNF alpha activity. Among these treatments Etanercept is a fusion protein that specifically targets TNF alpha. We performed a study on twelve psoriatic patients aimed at evaluating the effect of Etanercept treatment on the production and expression of TNF alpha and its receptors, in lesional and uninvolved psoriatic skin. We demonstrated that after three month of Etanercept treatment at 50 mg/wk, TNF, TNF-RI and TNF-RII immunostaining in lesional and non-lesional skin samples of patients was greatly reduced, suggesting that this treatment not only acts on stable lesional plaques, but also at a very early stage of the disease.